CSF3 and Decreased total neutrophil count: Results from the recent studies have demonstrated that accelerated epirubicin or doxorubicin with cyclophosphamide given at 2-week interval with G-CSF support could be well tolerated as same as given schedules over standard 3-week intervals in early breast cancer with fewer grade 3/4 neutropenia [9].